HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (H
ROCKVILLE, MD and SHENZHEN, CHINA, Jun 5, 2024 - (ACN Newswire) - - HighTide Therapeutics, Inc. (HKEX: 2511), a clinical ...